Infectious Disease Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Improving Care Through Azithromycin Research for Infants in Africa

This Phase 3 trial is testing whether giving the antibiotic azithromycin along with regular preventive treatment can reduce the number of deaths in infants and young children in Sierra Leone. If the study is successful, it could offer a new way to lower deaths caused by common infections such as malaria and pneumonia in children under two years old. The trial is active but not currently recruiting, focusing on a critical need to improve child survival in this region.

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

This study is examining the safety and effectiveness of nirsevimab, a monoclonal antibody designed to protect babies and young children from RSV, a common virus that can cause severe lung infections. If successful, nirsevimab could become a new prevention option to reduce RSV-related hospital stays and serious illness in children up to two years old. The trial is currently active in India and targets children during their first RSV season, when they are most vulnerable.

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children

This Phase 3 trial is testing a vaccine to protect children aged 1 to under 12 years from chikungunya virus, which is spread by mosquitoes and causes fever and joint pain. If this vaccine proves safe and effective, it could offer a new way to prevent chikungunya infections in children, especially in areas where outbreaks occur. The study is actively recruiting participants at multiple sites across the United States, Philippines, and Puerto Rico, helping to reach diverse populations at risk.

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

This study is testing a new mRNA-based vaccine aimed at preventing pandemic influenza in healthy adults aged 18 and older. This approach could lead to better protection against flu strains that have the potential to cause widespread outbreaks. The trial is recruiting up to 4,000 participants in the United States and United Kingdom, working toward improved pandemic preparedness.

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

This completed Phase 2 trial evaluated RNA vaccine candidates for COVID-19 in people aged 12 and older. With nearly 47,000 participants worldwide, the results help inform new vaccine options and booster strategies to keep up with COVID-19 and its variants. These findings support ongoing efforts to improve protection against the virus.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.